Blog

Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!

Photo of Zhen Su

Sep 14, 2024, 12:01

Zhen Su: Phase III NSCLC results are out – Ivonescimab vs. Pembrolizumab!

Zhen Su, CEO at Marengo Therapeutics, posted the following on LinkedIn:

“Phase III NSCLC Ivonescimab (Anti-VEGF/PD-1 Bispecific) from Akeso Inc. vs. Pembrolizumab (Anti PD-1) topline results are out at WCLC. PFS HR: 0.51 H2H and benefits observed across all major subgroups. Congratulations to AKESOBIO team! Really excited to see the next-gen IO reagents (bispecific IO) continue to push the boundaries higher for better patient care.

Still more to learn why it worked so well. But for the NSCLC patients who were enrolled in the investigational arm… doubling progress free survival is what matters!”

Source: Zhen Su/LinkedIn

Akeso Inc. Anti-PD-1 anti-VEGF bispecific IO cancer ivonescimab Marengo Therapeutics next-gen IO reagents NSCLC OncoDaily Oncology pembrolizumab Phase III trial WCLC 2024 Zhen Su

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage